TherapeuticsMD Inc (TXMD) Given Average Recommendation of “Buy” by Analysts
TherapeuticsMD Inc (NYSEMKT:TXMD) has been given an average recommendation of “Buy” by the eight ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $17.50.
A number of analysts have commented on the stock. Oppenheimer Holdings, Inc. upgraded shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 11th. Morgan Stanley assumed coverage on shares of TherapeuticsMD in a research note on Friday, September 8th. They set an “equal weight” rating and a $6.00 price target for the company. Finally, BidaskClub upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research note on Friday, September 8th.
Shares of TherapeuticsMD (TXMD) opened at $4.36 on Monday. TherapeuticsMD has a one year low of $3.50 and a one year high of $8.30.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.